<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>apid clinical validation of antibody-drug conjugates (ADCs) and renewing interest in targeted radioimmunoconjugates highlighted by commercial momentum and patent consolidation from Roche/Genentech, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Pfizer, and Hengrui are driving intense global competition across therapeutic oncology. With approximately 15 ADCs approved worldwide, over 200 candidates in clinical trials, and more than 400 in development, this study analyzes 3,761 patent families to map intellectual property positions, freedom-to-operate landscapes, and technological innovations across three core pillars: antibodies (liquid vs. solid tumors), linkers (cleavable vs. uncleavable), and payloads (topoisomerase 1 drugs, radioisotopes).Dublin, Aug. 17, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6217796/cancer-and-antibody-conjugates-patent-landscape?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=bqckx3&amp;utm_campaign=2326583+-+Cancer+%26+Antibody+Conjugates+Patent+Landscape+Report%3a+Evaluating+3%2c761+Patent+Families%2c+Linker-Payload+Technologies%2c+and+Strategies+of+Roche%2c+Daiichi+Sankyo%2c+Gilead%2c+and+AstraZeneca&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Cancer &amp; Antibody Conjugates Patent Landscape Analysis 2025">"Cancer &amp; Antibody Conjugates Patent Landscape Analysis 2025"</a> has been added to ResearchAndMarkets.com's offering. Cancer Antibody Conjugates Patent Landscape Report Delivers Strategic Insights into ADCs and Radioimmunoconjugates A comprehensive cancer antibody conjugates patent landscape report provides actionable intelligence on antibody-drug conjugates (ADCs), radioimmunoconjugates and the intellectual property strategies shaping the future of targeted oncology. Combining a PDF report of more than 100 slides with an Excel database covering 3,761 patent families, the study enables pharmaceutical companies, biotechnology firms, investors and research organizations to evaluate competition, identify innovation trends and support strategic decision-making. Cancer antibody conjugates continue to transform oncology by integrating monoclonal antibodies with cytotoxic drugs or radionuclides. Approximately 15 ADCs have received approval worldwide for hematologic malignancies and solid tumors, while more than 200 additional candidates are advancing through clinical trials and over 400 are reported to be in development. Radioimmunoconjugates are also attracting renewed interest as advances in immuno-oncology, radionuclide technologies and combination treatment strategies create new therapeutic opportunities. Despite strong clinical and commercial momentum, the sector faces significant challenges involving toxicity, treatment resistance, manufacturing complexity, conjugate stability and radioisotope handling. Against this backdrop, a detailed understanding of patent activity related to antibodies, targets, payloads, linkers, radionuclides and conjugation technologies is essential for assessing freedom to operate, anticipating competitive threats and identifying licensing or partnership opportunities. Key Report Features <ul><li>PDF report containing more than 100 slides of patent intelligence and competitive analysis</li><li>Excel database covering 3,761 analyzed patent families</li><li>Analysis of patent publication trends and filing activity by country</li><li>Ranking of the leading patent assignees in cancer antibody conjugates</li><li>Assessment of key players' intellectual property positions and relative patent portfolio strength</li><li>Patent segmentation by antibody application, linker technology and payload category</li><li>Analysis of industry collaborations, partnerships and intellectual property newcomers</li><li>Hyperlinks to an online patent database featuring updated legal status and supporting documents</li></ul> Patent Filing Activity Reflects Rapid ADC Market Expansion The patent landscape shows a prolonged exploratory period from the late 1970s through the mid-2000s, when annual filings remained limited and were largely driven by early pharmaceutical innovators and academic cancer centers. Patent activity accelerated as ADCs achieved clinical validation and gained traction in hematologic malignancies and breast cancer. Following 2010, annual patent filings increased sharply alongside the clinical development and approval of next-generation ADC products. Between 2018 and 2024, yearly filings more than doubled, approaching 500 new patent families annually. This growth was supported by investment in potent topoisomerase I inhibitor payloads, including deruxtecan- and govitecan-related technologies, as well as advances in cleavable linkers, site-specific conjugation and solid tumor applications. The competitive environment has also expanded beyond established pharmaceutical companies such as Roche/Genentech, Novartis, Pfizer, Bristol Myers Squibb, AbbVie, AstraZeneca and Gilead. Specialized biotechnology companies and rapidly growing Asian innovators, including Daiichi Sankyo and Hengrui, now contribute substantially to worldwide patent activity. Recent filing patterns indicate increasing portfolio consolidation and broader geographic protection within a market that remains highly innovative. Detailed Technology Segmentation The report organizes the cancer antibody conjugates patent landscape around three principal technology areas: antibodies, linkers and payloads. Eight segmentation categories are included. Antibody-related patents are classified by liquid cancer, liquid cancer only, solid cancer and solid cancer only, based on patent claims. Linker technologies are divided into cleavable and uncleavable categories, while payloads are segmented into drugs and radioisotopes. This structure supports targeted analysis of research priorities, technology maturity, portfolio overlap and competitive positioning. Users can compare patent ownership across individual technology segments and identify areas with high filing intensity or potential opportunities for differentiation. New Entrants and Competitive Opportunities The study identifies 147 intellectual property newcomers in the cancer antibody conjugates landscape. These organizations include start-ups and established companies filing their first patents in the field. China accounts for 76 of the identified newcomers, highlighting the country's growing role in ADC research, manufacturing and commercialization. Monitoring these emerging companies can help established market participants identify potential acquisition targets, licensing partners and future competitors. Profiles of Leading Patent Owners Profiles of major patent assignees include company background, portfolio composition, patent publication trends, geographic coverage and active patents by technical segment. The report also examines the technological content of strategically important patents and provides relevant clinical trial information, supporting a clearer assessment of each company's innovation strategy and market position. The accompanying Excel database enables multi-criteria searches across all 3,761 patent families. Available data include publication numbers, priority dates, titles, abstracts, assignees, legal status, technology segmentation and hyperlinks to original patent documents. Access to the online patent database further supports ongoing monitoring through updated legal status information for individual patent records. Key Topics Covered: INTRODUCTION <ul><li>What are antibody conjugates?</li><li>First approvals, opportunities &amp; challenges in oncology</li><li>Scope of the report</li><li>Patent search, selection and analysis</li><li>Search strategy</li><li>Excel database</li><li>Reading guide</li></ul> EXECUTIVE SUMMARY PATENT LANDSCAPE OVERVIEW <ul><li>Time evolution of patent publications</li><li>Ranking of most prolific patent applicants</li><li>Current legal status of the main players</li><li>Patent legal status of the corpus</li><li>Mapping of main current IP holders</li><li>Time evolution of main patent assignees</li></ul> NEWCOMERS <ul><li>Chinese companies</li><li>Other companies</li></ul> IP POSITION OF MAIN APPLICANTS <ul><li>IP leadership of patent applicants</li><li>IP prior art blocking potential of patent applicants</li><li>Patent citation</li><li>Strength index of patent portfolios</li></ul> PATENT SEGMENTATION <ul><li>Definition</li><li>Main assignees by technology</li><li>Antibody moiety</li><li>Linker</li><li>Payload moiety</li></ul> IP PROFILE OF KEY PLAYERS <ul><li>Overview, key patents &amp; clinical trials of: <ul><li>Pfizer</li><li>Genentech</li><li>Roche</li><li>AbbVie</li><li>AstraZeneca</li><li>Gilead</li></ul> </li></ul> METHODOLOGY <ul><li>Patent search, selection and analysis</li><li>Terminologies</li><li>Key IP players</li><li>Key patents</li></ul> A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Pfizer</li><li>Genentech-Roche</li><li>AbbVie</li><li>AstraZeneca</li><li>Gilead</li><li>Roche</li><li>Daiichi Sanko</li><li>Jiangsu Hengrui</li><li>Astellas Pharma</li><li>Novartis</li><li>Bristol-Myers Squibb</li><li>ADC Therapeutics</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6217796/cancer-and-antibody-conjugates-patent-landscape?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=bqckx3&amp;utm_campaign=2326583+-+Cancer+%26+Antibody+Conjugates+Patent+Landscape+Report%3a+Evaluating+3%2c761+Patent+Families%2c+Linker-Payload+Technologies%2c+and+Strategies+of+Roche%2c+Daiichi+Sankyo%2c+Gilead%2c+and+AstraZeneca&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/8k6l7w</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YzMxYmZiMGItYTMyNy00Y2Y0LThiMjYtYWRhZjQwNWM0NmVjLTEwMjY3MzctMjAyNi0wOC0xNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn